FDA Panel Backs Four Peptides for Compounding: The Votes, the Evidence Dispute, and What It Actually Changes
Listen to Article
Part 1: Introduction
Four peptides cleared PCAC, but every yes came from June appointees, FDA scientists said no to all seven, and the law did not change.
Four peptides cleared the FDA's Pharmacy Compounding Advisory Committee on Thursday, and the coverage is going to compress that into a headline about approval. The record is more interesting than the headline. Every vote in favor came from members seated on the committee six weeks ago, the agency's own scientists had recommended against all seven substances under review, and the legal status of every one of them is the same tonight as it was Wednesday. Here is what happened, what the evidence fight was about, and what it does and does not change.
PCAC recommended four peptides for the 503A Bulks List — BPC-157, KPV, and TB-500 at 8-6, MOTs-C at 7-5 — over the written objection of FDA's own review staff. A recommendation is not an addition.
Key Takeaways
- All four peptides reviewed July 23 cleared the committee: BPC-157, KPV, and TB-500 at 8-6, and MOTs-C at 7-5.
- Every vote in favor came from members newly appointed to the committee in June 2026. The holdover members voted no.
- FDA scientists recommended against all seven in a 68-page briefing document applying the four-factor test at 21 C.F.R. 216.23.
- A recommendation is not a rule. Adding a substance to the 503A Bulks List under 21 U.S.C. 353a requires notice-and-comment rulemaking.
- Nothing about the legal status of these substances changed Thursday. Compounding them still falls outside the 503A exemption.
What the Committee Was Actually Deciding
No vote taken Thursday moves any peptide toward approved drug status. The question was narrower.
Section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, exempts pharmacy-compounded preparations from three requirements that otherwise apply to drugs: new drug approval, current good manufacturing practice, and standard labeling. That exemption is conditional. One condition governs the prescription, which must be patient-specific. A separate condition governs the raw ingredient. A bulk drug substance qualifies only if it complies with a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List.
These peptides satisfy none of the first two routes. The Bulks List is the only available path, and that is what the committee was voting on.
The history matters for reading the current status correctly. In 2023 FDA placed nineteen peptide substances into Category 2 of its interim compounding policy, meaning compounding was not permitted and the agency could take enforcement action. In April 2026 a group of them came out of Category 2, which is what made this review possible. That was widely reported as a loosening, and in a limited sense it was. It was not authorization. A substance can sit outside Category 2 and still fail the eligibility conditions in 21 U.S.C. 353a, which is precisely where these peptides sit today.
The Four Votes
Each substance drew two separate votes, one for the free base form and one for the acetate form, because both were under review.
| Peptide | Indication reviewed | Vote | Abstentions | |---|---|---|---| | BPC-157 | Ulcerative colitis | 8-6 in favor | 1 | | KPV | Wound healing, inflammatory conditions | 8-6 in favor | 1 | | TB-500 | Wound healing | 8-6 in favor | 1 | | MOTs-C | Obesity, osteoporosis | 7-5 in favor | 2 |
The composition of those margins is the part worth sitting with. Reporting on the meeting indicates that for BPC-157, KPV, and TB-500, all eight votes in favor came from members newly appointed to the committee in June. The six no votes came from the holdover membership. On MOTs-C, seven of the new appointees voted yes, five members voted no, and two abstained, including one of the new appointees.
That is not a committee that weighed the evidence and split. That is a committee that split along the line of when its members were seated. FDA reconstituted the roster in June, and several new members have professional or commercial ties to peptide therapy, including clinicians who prescribe and businesses that sell. Additional temporary voting members were added days before the meeting. Those facts are part of the public record of this proceeding, and they will shape how the agency, reviewing courts, and the trade press treat the outcome.
What FDA Scientists Argued
Agency review staff produced a briefing document running 68 pages and recommended against adding any of the seven substances. The analysis applied the four-factor framework at 21 C.F.R. 216.23: physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety.
On effectiveness, staff found insufficient evidence to reach a conclusion about BPC-157 for ulcerative colitis and noted that FDA-approved treatments for that condition already exist. For KPV, TB-500, and MOTs-C, staff reported no human clinical data at all. The evidence base rests substantially on animal work.
On characterization, staff flagged a problem that gets little attention outside regulatory circles. These substances lack standardized naming conventions and consistent quality specifications. Two products sold as the same peptide are not necessarily the same molecule at the same purity. That is a threshold problem for a list meant to tell a pharmacist what they may compound with.
On safety, the recurring concerns were immunogenicity, contamination risk, and manufacturing consistency. TB-500 and MOTs-C also carry World Anti-Doping Agency prohibited status. The document separately noted the scale of consumer interest, including more than fifty million views on BPC-157 tagged video content across YouTube and TikTok and over one hundred thousand members in peptide-focused online communities.
What the Majority Argued Back
The affirmative case rested less on demonstrated efficacy than on two other propositions.
The first was an absence of established harm. Supporters emphasized that the safety record shows no clear signal of serious injury and treated that absence as sufficient. This is a burden-shifting argument. It asks whether there is enough evidence to disprove safety rather than enough to establish effectiveness, which inverts the framework the agency applies.
The second was the gray market. Proponents argued that people are already taking these compounds in large numbers, sourced from vendors labeling product for research use only, with no pharmacist involvement, no verified potency, and no clinical oversight. A regulated compounding channel, on this view, is safer than the channel that exists now. That argument has real force and it is the strongest thing the majority had.
Dissenting members made a point worth attention. Adding a substance to the Bulks List is not an efficacy finding, but consumers will read it as one. A member from the Keck School of Medicine at USC warned specifically that the public would perceive the vote as an endorsement carrying the weight of FDA approval, which it does not.
A procedural dispute also surfaced. During public comment, proponents presented data supporting uses beyond the indications staff had reviewed. That material was not always reflected in the staff presentations, which frustrated some members. Staff responded that everything submitted by the deadline had been reviewed. Public comment ran close to two hours and came predominantly from clinicians whose businesses offer peptide therapy and from compounding pharmacy industry representatives.
What Happens Next
The recommendation goes to FDA. The agency is not bound by it, though it usually follows its advisory committees. Going against a PCAC recommendation is unusual and has happened before.
If FDA accepts, the mechanism is notice-and-comment rulemaking under the Administrative Procedure Act. The agency publishes a proposed rule amending the 503A Bulks List, opens a comment period, addresses the comments received, and publishes a final rule. Twelve months is the fast case. This one will draw substantial comment from both directions.
Three other substances, emideltide, semax, and epitalon, were scheduled for Friday. The committee took them up and recommended two of the three, bringing the two-day total to six of seven. Epitalon cleared 7 to 4 for insomnia. Semax cleared 8 to 5 for migraine and two neurological conditions. Emideltide, considered for opioid withdrawal, chronic insomnia, and narcolepsy, was rejected 6 to 7, the only rejection of the meeting. Members who voted against emideltide cited the same evidence gap FDA staff had flagged for all seven. A further meeting is expected before the end of February 2027 covering additional substances, including an injectable form of GHK-Cu, melanotan II, and dihexa.
What Changed Thursday, and What Did Not
What changed is the direction of travel. Four favorable recommendations against a uniform staff recommendation to reject is a meaningful signal about where this agency is heading under current leadership.
What did not change is the legal status of any of these substances. A preparation compounded from a bulk substance that fails the 21 U.S.C. 353a conditions falls outside the exemption, which makes it an unapproved new drug under 21 U.S.C. 355 and misbranded under 21 U.S.C. 352. That analysis reads the same today as it did Wednesday. A recommendation to add a substance to a list is not the addition of that substance to the list.
There is also an unresolved question about indications. Staff reviewed each substance against specific conditions: ulcerative colitis, wound healing, obesity and osteoporosis. Those are not the uses driving consumer demand. If FDA ultimately lists these substances, prescribers generally retain discretion to prescribe beyond the reviewed indication, which means a listing evaluated on ulcerative colitis data could function in practice as access for recovery and longevity use. Whether the agency closes that gap in its rulemaking is one of the more consequential open items from this meeting.
Practical Notes for Operators and Prescribers
Four things follow from the record above for anyone running a pharmacy, clinic, telehealth platform, or peptide retail business.
A headline is not authorization. Some version of "FDA approves BPC-157" will circulate widely over the next several days. A committee recommended. The agency has not acted, and the rule does not exist yet.
Scaling volume during the interim period carries a specific risk. Marketing and dispensing that expand in the weeks after a favorable advisory vote generate a documented increase in activity during a window when no legal pathway existed. That record is easy to assemble later and it will not have been assembled by the government.
A patient-specific prescription addresses one 503A condition and does nothing about substance eligibility. Prescribers who believe the patient-specific structure resolves the issue are working from an incomplete reading of the statute.
Florida operators carry a second layer independent of federal law. The Department of Health can pursue unprofessional conduct or prescribing outside prevailing standards without waiting on a federal case, on a lower burden and a shorter timeline. Compensation arrangements tied to patient origination also implicate the Florida Patient Brokering Act, Fla. Stat. 817.505, where the employee and personal services safe harbors do not reach contractor structures as commonly written.
Agents from FDA Office of Criminal Investigations and HHS-OIG conduct interviews that operators mistake for regulatory check-ins. A false statement in that interview is an independent felony under 18 U.S.C. 1001, and it is frequently the cleanest count in an indictment. You may decline the interview and have counsel arrange it on your terms.
"A prescriber holding written confirmation from a pharmacy about sourcing and regulatory status stands in a materially different position than one who assumed. Good faith reliance is a real defense in this space, and it is documentary."— Aaron M. Cohen, Principal Attorney
Common Questions
AMC Defense Law follows FDA compounding policy and enforcement as part of its federal practice. If you operate a pharmacy, clinic, or telehealth platform in this space and want to understand how a final rule would affect your obligations, or if you have received an inquiry from a regulator, the firm handles these matters in Florida and nationwide. Consultations are confidential.
The window where charging decisions are still fluid is open right now. It closes without announcement.
If you or your loved ones are under federal investigation involving peptides, GLP-1 compounds, or med spa operations in Florida, call Aaron M. Cohen, 24 hours a day, at 561.542.5494 to get help.
This article is provided for general informational purposes only and does not constitute legal or medical advice. Reading it does not create an attorney-client relationship. It describes regulatory developments as of July 24, 2026, which remain subject to change. Nothing here should be read as a recommendation regarding the use of any substance discussed.
Listen to Article
Part 1: Introduction
Four peptides cleared PCAC, but every yes came from June appointees, FDA scientists said no to all seven, and the law did not change.
Aaron M. Cohen
Principal Attorney
Aaron M. Cohen is a nationally recognized criminal defense attorney with over 30 years of experience representing individuals and entities in complex criminal investigations and prosecutions across the United States.
View Attorney ProfileRelated Analysis
FDA Recommends Against Seven Peptides for the 503A Bulks List: What Compounders, Clinics, and Peptide Sellers Need to Know About Federal Exposure
The FDA just recommended against adding BPC-157, TB-500, and five more peptides to the 503A list. If you compound or sell them, know your federal exposure now.
Peptide "Legalization" and Federal Criminal Exposure: What Florida Compounders, Sellers, and Clinics Need to Know in 2026
The FDA removed 12 peptides from its Category 2 list in April 2026. That is not legalization. The gap between what the headlines say and what the law permits is where federal criminal cases get built.
Free Heart Screens, Phantom Diagnoses: Why Federal Prosecutors Are Targeting Florida Cardiology and Diagnostic-Testing Practices
A South Florida cardiology operation billed $89M using free heart checks that produced diagnoses patients never had. The 2026 takedown shows how prosecutors build these cases and why the pre-indictment window is the only one that matters.